This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Sign in
Sign In or Register
Sign out

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Explore Content

The content of this website has been produced in line with the BESPONSA®▼ (inotuzumab ozogamicin) Summary of Product Characteristics for Great Britain and is intended for Healthcare Professionals based in Great Britain. BESPONSA▼ Prescribing Information for Great Britain click here. BESPONSA▼ Prescribing Information for Northern Ireland click here. Adverse event reporting information can be found at the bottom of the page.

INO-VATE PubExplainer video

Duration: 03:05

This animated video discusses the INO-VATE1 randomised, multicentre, open label Phase III study for BESPONSA versus standard chemotherapy in relapsed or refractory Acute Lymphoblastic Leukaemia (ALL) with particular reference to the following:

  • Inclusion criteria
  • Study design
  • Patients' baseline characteristics
  • Results from the co-primary endpoints of
    • Overall survival improvement
    • Complete remission improvement
  • Results from the secondary endpoint in patients who underwent follow-up HSCT
  • The rate of MRD negativity in those patients achieving CR/CRi
  • Adverse Events profile
    • Including incidence of VOD/SOS 

  • BESPONSA mechanism of action
  • Phase III INO-VATE study1: BESPONSA vs. standard chemotherapy​​​​​​​
    • Study population and eligibility
    • Study endpoints: Remission Rates and Overall Survival
    • Adverse Event profile
    • Management of hepatic toxicity and veno-occlusive disease and risk factors
    • Bridging to transplantation
    • Number of cycles required to achieve remission rates

Developments in Leukaemia Care

Watch Professor David Marks discuss targeted therapies and the INO-VATE study, including 3 year follow up and impact of allogeneic bone marrow transplantation on survival

Learn More

Management of Refractory/Relapsed ALL

Hear Professor David Marks discuss the INO-VATE study including MRD negativity, long term survival and reducing risks of veno-occlusive disease

Learn More

CR, complete remission; CRi, complete remission with incomplete haematological recovery of peripheral blood counts; HSCT, Haematopoietic Stem Cell Transplantation; MRD, minimal residual disease; SOS, sinusoidal obstruction syndrome; VOD, veno-occlusive disease 
 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.
  1. ​​​​​​​Kantarjian HM, et al. New Engl J Med. 2016;375:740-53.
PP-INO-GBR-0641. February 2022

Register to receive tailored marketing information from Pfizer by email

Stay up to date with the latest relevant healthcare, medical and promotional information about medicines and vaccines promoted by Pfizer.

PP-PFE-GBR-2809. March 2021

Sign up now

Fast Facts

Download the Fast Facts Guide holding the key information for BESPONSA including mode of action, INO-VATE study design, INO-VATE results; efficacy and safety profile. Summary of Product Characteristics (SmPC) should be consulted for full guidance.

Download here

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021



OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.This is an interstitial message to prompt a HCP before they login.

If you have already registered with and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.

Would you like to register or sign in now?